The Metabolomic Footprint of Liver Fibrosis
Cells · 2024
DOI: 10.3390/cells13161333 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Diren Beyoğlu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Administrative Sciences, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA 01…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Metabolomics. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Both experimental and clinical liver fibrosis leave a metabolic footprint that can be uncovered and defined using metabolomic approaches. Metabolomics combines pattern recognition algorithms with analytical chemistry, in particular, 1H and 13C nuclear magnetic resonance spectroscopy (NMR), gas chromatography–mass spectrometry (GC–MS) and various liquid chromatography–mass spectrometry (LC–MS) platforms. The analysis of liver fibrosis by each of these methodologies is reviewed separately. Surprisingly, there was little general agreement between studies within each of these three groups and also between groups. The metabolomic footprint determined by NMR (two or more hits between studies) comprised elevated lactate, acetate, choline, 3-hydroxybutyrate, glucose, histidine, methionine, glutamine, phenylalanine, tyrosine and citrate. For GC–MS, succinate, fumarate, malate, ascorbate, glutamate, glycine, serine and, in agreement with NMR, glutamine, phenylalanine, tyrosine and citrate were delineated. For LC–MS, only β-muricholic acid, tryptophan, acylcarnitine, p-cresol, valine and, in agreement with NMR, phosphocholine were identified. The metabolomic footprint of liver fibrosis was upregulated as regards glutamine, phenylalanine, tyrosine, citrate and phosphocholine. Several investigators employed traditional Chinese medicine (TCM) treatments to reverse experimental liver fibrosis, and a commentary is given on the chemical constituents that may possess fibrolytic activity. It is proposed that molecular docking procedures using these TCM constituents may lead to novel therapies for liver fibrosis affecting at least one-in-twenty persons globally, for which there is currently no pharmaceutical cure. This in-depth review summarizes the relevant literature on metabolomics and its implications in addressing the clinical problem of liver fibrosis, cirrhosis and its sequelae.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical and Administrative Sciences, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA 01119, USA.
- Division of Gastroenterology, Hepatology and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
ORCID-Profile: Diren Beyoğlu, Yury V Popov, Jeffrey R Idle
Zitieren
APA
Beyoğlu, D., Popov, Y. V., & Idle, J. R. (2024). The Metabolomic Footprint of Liver Fibrosis. Cells. https://doi.org/10.3390/cells13161333
Vancouver
Beyoğlu D, Popov YV, Idle JR. The Metabolomic Footprint of Liver Fibrosis. Cells. 2024. doi:10.3390/cells13161333
BibTeX
@article{Beyolu2024,
author = {Beyoğlu, Diren and Popov, Yury V and Idle, Jeffrey R},
title = {The Metabolomic Footprint of Liver Fibrosis},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13161333}
}
EUVIMED